UPSTREAM BIO, INC. Payments for Repurchase of Initial Public Offering
UPSTREAM BIO, INC. (UPB) reported Payments for Repurchase of Initial Public Offering of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2026-08-11
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for the quarter ending 2026-06-30 was $0.00.
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for the quarter ending 2025-06-30 was $0.00.
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for the quarter ending 2025-03-31 was $34.00K.
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for fiscal 2025 was $34.00K, a 99.13% decline from fiscal 2024.
- UPSTREAM BIO, INC. payments for repurchase of initial public offering for fiscal 2024 was $3.90M.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $34.00K 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $34.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $34.00K 10-Q · filed 2026-05-13 | ||
| 2024-12-31 | $3.90M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |